EGFR and lung cancer: MET-mutated NSCLC has been correlated with an older age at diagnosis compared with EGFR, KRAS, and BRAF-mutant lung cancers, with a median age of 72.5 years; furthermore, two thirds of patients harboring MET exon 14 mutations have been reported to be current or former smokers, but in a recent Italian study, no differences in MET amplifications in relation with the smoking status were found in naïve patients with lung adenocarcinoma [25].